Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Oficina francesa de transferencia de tecnología ofrece un tratamiento preventivo y terapéutico contra alergias alimentarias

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20180315002
Publicado:
19/04/2018
Caducidad:
20/04/2019
Resumen:
Una oficina francesa de transferencia de tecnología ofrece un nuevo tratamiento contra las alergias alimentarias basado en la administración de un fármaco comercializado (interleucina-2 - IL2) a una dosis inferior. El uso de IL-2 a una dosis inferior ha demostrado resultados terapéuticos prometedores en un modelo de ratón de alergia inducida por ovoalbúmina (alergia al huevo), ofreciendo una efectividad a largo plazo en un estudio realizado durante 10 meses. Esta nueva tecnología es de utilidad para el mercado de tratamiento y prevención de alergias alimentarias. La oficina busca compañías farmacéuticas y biotecnológicas con el fin de establecer acuerdos de licencia o cooperación técnica.

Details

Tittle:
A French Technology Transfer Office offers a preventive and therapeutic treatment against food allergies
Summary:
A French Technology Transfer Office (TTO) offers a new treatment against food allergies thanks to the administration of a commercialized drug at a lower dosage. This new technology is useful for the food allergy therapy and prevention market.
The French TTO is looking for interested pharmaceutical corporations or biotechnology SMEs for a licensing agreement or for a technical cooperation agreement.
Description:
A French TTO acting on behalf of major life science research labs in Paris region, has patented the use of interleukin-2 (IL2) at low dosage to prevent and cure food allergy by inducing non-specific tolerance against food allergens.

Food allergies are an increasing health issue, worldwide. There is no treatment commercially available to treat them. The current standard of care is strict avoidance of the offending allergens and immediate access to rescue medications, such as epinephrine and antihistamines. Indeed, the great majority of allergic patients are treated by symptomatic medication using drugs that exhibit general anti-inflammatory activity and/or reverse bronchoconstriction or vasodilatation. However, symptomatic medication fails to target the mechanisms underlying allergic disease, and often has only short activity.
Specific immunotherapies showed good results for some allergies but these strategies showed rather low efficacy in the case of food allergies and more precisely for peanut or egg allergies. There is therefore a need for an effective long-term treatment and protection against food allergies.

The use of IL-2 at a lower dosage in the case of food allergy showed promising therapeutic results in a mouse model of ovalbumin induced allergy (egg allergy), providing a long-term effectiveness over a 10-month period study.
This treatment also provides a good preventive treatment against peanut allergy and promising results for its therapeutic effect.
The clinical symptoms due to these allergies (pruritis, piloerection, oedema, lethargy or diarrhea) are drastically reduced.

The partner sought could be a company interested in :
- a license agreement (the TTO is able to negotiate directly the intellectual property transactions for specific applications), or
- a technical cooperation agreement to validate the preclinical data and launch clinical trials

Advantages and Innovations:
Desensitization (progressive administration of low-doses allergens) for food allergies could be a solution but implies the development of a specific treatment for each allergy.
The development of hypoallergenic food could be also an alternative but it means to launch many R-Y-D efforts to offer this new kind of food.
A drug for treating several types of food allergy could be a very good solution.

The advantages of this new technology are:
-therapeutic treatment
-preventive treatment
-new indication of a marketed molecule at a lower dosage (drug safety has already been validated)
-universal treatment for food allergies
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
An international patent application claiming the use of IL2 for treating food allergy has been filed in 2015 with extensions in USA (US), Europe (EP), Japan (JP), CN (China) and Canada (CA).

Partner sought

Type and Role of Partner Sought:
The partner sought could be:
-a company involved in the field of allergy interested in developing some more efficient therapeutic solutions or,
-a company developing immunomodulation strategies.
This technology could interest drugs formulation companies or commercializing companies (pharma or biotech).

Technical cooperation agreement: the potential industrial partner should be interested to invest in co-development for another specific food allergy (milk, fish,...).

License agreement: the potential industrial partner should be interested in negotiating a license agreement in order to commercialize a new drug using the patented compound for peanut or egg allergies (after launching clinical trials).


Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Keywords

Technology Keywords:
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos